Vulvovaginitis and Cervicitis

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 1, Issue , 2014, Pages 1358.e1-1371.e2

  McCormack, William M ^a   Augenbraun, Michael H ^a  

^a Downstate Health Sciences University   (United States)

Author keywords

Atrophic vaginitis; Bacterial vaginosis; Candida vaginitis; Candidiasis; Cervicitis; Chlamydia trachomatis; Desquamative; Estrogen deficiency vaginitis; Gardnerella vaginalis; Gonorrhea; Inflammatory vaginitis; Metronidazole; Tinidazole; Trichomonas vaginalis; Trichomoniasis; Vaginitis; Vestibulitis; Vulvitis

Indexed keywords

EID: 84944575908     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00110-7     Document Type: Chapter

References (210)

1. McCormack WM, Zinner SH, McCormack WM The incidence of genitourinary infections in a cohort of healthy women. Sex Transm Dis 1994, 21:63-64.
2. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 2011, 108(suppl 1):4680-4687.
3. 2-generating lactobacilli. J Infect Dis 1991, 164:94-100.
4. Wiesenfeld HC, Hillier SL, Krohn MA, et al. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003, 36:663-668.
5. Soper DE, Bump RC, Hurt WG Bacterial vaginosis and trichomoniasis are risk factors for cuff cellulitis after abdominal hysterectomy. Am J Obstet Gynecol 1990, 163:1016-1023.
6. Singh RH, Zenilman JM, Brown KM, et al. The role of the physical examination in diagnosing common causes of vaginitis: a prospective study. Sex Transm Infect 2013, 89:185-190.
7. Hammerschlag MR, Guillen CD Medical and legal implications of testing for sexually transmitted infections in children. Clin Microbiol Rev 2010, 23:493-506.
8. Xu J, Schwartz K, Bartoces M, et al. Effect of antibiotics on vulvovaginal candidiasis: a metroNet study. J Am Board Fam Med 2008, 21:261-268.
9. Stern JE, Givan AL, Gonzalez JL, et al. Leukocytes in the cervix: a quantitative evaluation of cervicitis. Obstet Gynecol 1998, 91:987-992.
10. Rein MF, Shih LM, Miller JR, et al. Use of a lactoferrin assay in the differential diagnosis of female genital tract infections and implications for the pathophysiology of bacterial vaginosis. Sex Transm Dis 1996, 23:517-521.
11. Silverman EM, Silverman AG Persistence of spermatozoa in the lower genital tracts of women. JAMA 1978, 240:1875-1877.
12. Rothenberg RB, Simon R, Chipperfield E, et al. Efficacy of selected diagnostic tests for sexually transmitted diseases. JAMA 1976, 235:49-51.
13. McCormack WM, Starko KM, Zinner SH Symptoms associated with vaginal colonization with yeast. Am J Obstet Gynecol 1988, 158:31-33.
14. Lossick JG, Kent HL Trichomoniasis: trends in diagnosis and management. Am J Obstet Gynecol 1991, 165:1217-1222.
15. DeMeo LR, Draper DL, McGregor JA, et al. Evaluation of a deoxyribonucleic acid probe for the detection of Trichomonas vaginalis in vaginal secretions. Am J Obstet Gynecol 1996, 174:1339-1342.
16. Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis 2007, 45:194-198.
17. Kurth A, Whittington WL, Golden MR, et al. Performance of a new, rapid assay for detection of Trichomonas vaginalis. J Clin Microbiol 2004, 42:2940-2943.
18. Munson E, Napierala M, Olson R, et al. Impact of Trichomonas vaginalis transcription-mediated amplification-based analyte-specific-reagent testing in a metropolitan setting of high sexually transmitted diseases prevalence. J Clin Microbiol 2008, 46:3368-3374.
19. Coleman JS, Gaydos CA, Witter F Trichomonas vaginalis vaginitis in obstetrics and gynecology practice: new concepts and controversies. Obstet Gynecol Surv 2013, 68:43-50.
20. Lobo TT, Feijo G, Carvalho SE, et al. A comparative evaluation of the Papanicolaou test for the diagnosis of trichomoniasis. Sex Transm Dis 2003, 30:694-699.
21. Workowski KA, Berman SM Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006, 55(RR-11):1-94. Centers for Disease Control and Prevention.
22. Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD surveillance network, 2009-2010. Emerg Infect Dis 2012, 18:939-943.
23. Lossick JG, Muller M, Gorrell TE In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis 1986, 153:948-955.
24. Dombrowski MP, Sokol RJ, Brown WJ, et al. Intravenous therapy of metronidazole-resistant Trichomonas vaginalis. Obstet Gynecol 1987, 69:524-525.
25. Crowell AL, Sanders-Lewis KA, Secor WE In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother 2003, 47:1407-1409.
26. Nailor MD, Sobel JD Tinidazole for the treatment of vaginal infections. Expert Opin Investig Drugs 2007, 16:743-751.
27. Livengood CH, Lossick JG Resolution of resistant vaginal trichomoniasis associated with the use of intravaginal non-oxynol-9. Obstet Gynecol 1991, 78:954-956.
28. Antonelli NM, Diehl SJ, Wright JW A randomized trial of intravaginal nonoxynol 9 versus oral metronidazole in the treatment of vaginal trichomoniasis. Am J Obstet Gynecol 2000, 182:1008-1010.
29. Narcisi EM, Secor WE In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrob Agents Chemother 1996, 40:1121-1125.
30. Schwartz J Tricofuron therapy of Trichomonas vaginitis. Obstet Gynecol 1956, 7:312-314.
31. Aggarwal A, Shier RM Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification. J Obstet Gynaecol Can 2008, 30:55-58.
32. duBouchet L, McGregor JA, Ismail M, et al. A pilot study of metronidazole vaginal gel versus oral metronidazole for the treatment of Trichomonas vaginalis vaginitis. Sex Transm Dis 1998, 24:176-179.
33. Martinotti MG, Savoia D Effect of some steroid hormones on the growth of Trichomonas vaginalis. G Batteriol Virol Immunol 1985, 78:52-59.
34. Azuma T A study of the parasitizing condition of Trichomonas vaginalis with special reference to the relationship between estrogen and the growth of Trichomonas vaginalis. J Jpn Obstet Gynecol Soc 1968, 15:168-172.
35. Sharma R, Pickering J, McCormack WM Trichomoniasis in a postmenopausal woman cured after discontinuation of estrogen replacement therapy. Sex Transm Dis 1997, 24:543-545.
36. Helms DJ, Mosure DJ, Secor WE, et al. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008, 198:370.e7.
37. Cu-Uvin S, Ko H, Jamieson DJ, et al. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HlV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002, 34:1406-1411.
38. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001, 183:1017-1022.
39. Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis 2008, 197:548-554.
40. Minkoff H, Grunebaum AN, Schwarz RH, et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol 1984, 150:965-972.
41. Cotch MF, Pastorek JG, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis 1997, 24:353-360.
42. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001, 345:487-493.
43. Caro-Paton T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997, 44:179-182.
44. Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995, 172:525-529.
45. Piper JM, Mitchel EF, Ray WA Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993, 82:348-352.
46. Vermitsky JP, Self MJ, Chadwick SG, et al. Survey of vaginal flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008, 46:1501-1503.
47. Spinillo A, Capuzzo E, Gulminetti R, et al. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol 1997, 176:138-141.
48. Horowitz BJ, Edelstein SW, Lippman L Candida tropicalis vulvovaginitis. Obstet Gynecol 1985, 66:229-232.
49. Geiger AM, Foxman B, Sobel JD Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C. glabrata and no Candida. Genitourin Med 1995, 75:304-307.
50. Spinillo A, Capuzzo E, Egbe TO, et al. Torulopsis glabrata vaginitis. Obstet Gynecol 1995, 85:993-998.
51. Ray D, Goswami R, Banerjee U, et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007, 30:312-317.
52. Sobel JD, Vazquez J, Lynch M, et al. Vaginitis due to Saccharomyces cerevisiae: epidemiology, chemical aspects, and therapy. Clin Infect Dis 1993, 16:93-99.
53. McCullough MJ, Clemons KV, Farina C, et al. Epidemiological investigation of vaginal Saccharomyces cerevisiae isolates by a genotypical method. J Clin Microbiol 1998, 36:557-562.
54. Sobel JD Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985, 1523:924-935.
55. Sobel JD Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992, 14(suppl 1):S148-S153.
56. Agnew KJ, Hillier SL The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization with lactobacilli. Sex Transm Dis 1995, 22:269-273.
57. Larsen B Vaginal flora in health and disease. Clin Obstet Gynecol 1993, 36:107-121.
58. Sonnex C Influence of ovarian hormones on urogenital infection. Sex Transm Infect 1998, 74:11-19.
59. Spinillo A, Capuzzo E, Nicola S, et al. The impact of oral contraception on vulvovaginal candidiasis. Contraception 1995, 51:293-297.
60. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995, 18:1415-1427.
61. Elegbe IA, Botu M A preliminary study on dressing patterns and incidence of candidiasis. Am J Public Health 1982, 72:176-177.
62. Elgebe IA, Elgebe I Quantitative relationships of Candida albicans infections and dressing patterns in Nigerian women. Am J Public Health 1983, 73:450-452.
63. Heidrich FE, Berg AO, Bergman JJ Clothing factors and vaginitis. J Fam Pract 1984, 19:491-494.
64. Sobel JD Vulvovaginal candidiasis: a comparison of HIV-positive and -negative women. Int J STD AIDS 2002, 13:358-362.
65. Shifrin E, Matityahu D, Feldman J, et al. Determinants of incident vulvovaginal candidiasis in human immunodeficiency virus-positive women. Infect Dis Obstet Gynecol 2000, 8:176-180.
66. Sobel JD Vaginitis. N Engl J Med 1997, 337:1896-1903.
67. Gieger AM, Foxman B, Gillespie BW The epidemiology of vulvovaginal candidiasis among university students. Am J Public Health 1995, 85:1146-1148.
68. Gieger AM, Foxman B Risk factors in vulvovaginal candidiasis: a case controlled study among university students. Epidemiology 1996, 7:182-187.
69. Odds FC Genital candidosis. Clin Exp Dermatol 1982, 7:345-354.
70. Odds FC Candida and Candidosis 1979, University Park Press, Baltimore.
71. Garcia-Tamayo J, Castillo G, Martinez AJ Human genital candidiasis: histochemistry, scanning and transmission electron microscopy. Acta Cytol 1982, 26:7-14.
72. Kimura LH, Pearsall NN Relationship between germination of Candida albicans and increased adherence to human buccal epithelial cells. Infect Immun 1980, 28:464-468.
73. King RD, Lee JC, Morris AL Adherence of Candida albicans and other Candida species to mucosal epithelial cells. Infect Immun 1980, 27:667-674.
74. Sobel JD, Muller G Ketoconazole in the prevention of experimental candidal vaginitis. Antimicrob Agents Chemother 1984, 25:281-282.
75. Witkin SS, Jeremias J, Ledger WJ A localized vaginal allergic response in women with recurrent vaginitis. J Allergy Clin Immunol 1988, 81:412-416.
76. Rigg D, Miller MM, Metzger WJ Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990, 162:332-336.
77. Ferris DG, Nyirjesy P, Sobel JD, et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 2002, 99:419-425.
78. Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Am J Obstet Gynecol 1995, 172:1263-1268.
79. Weissenbacher S, Witkin SS, Tolbert V, et al. Value of Candida polymerase chain reaction and vaginal cytokine analysis for the differential diagnosis of women with recurrent vulvovaginitis. Infect Dis Obstet Gynecol 2000, 8:244-247.
80. Nyirjesy P, Seeney SM, Terry Grody MH, et al. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol 1995, 173:820-823.
81. Sobel JD, Kapernick PS, Zervos M, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001, 185:363-369.
82. Sobel JD Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 1986, 315:1455-1458.
83. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004, 351:876-883.
84. Singh S, Sobel JD, Bhargava P, et al. Vaginitis due to Candida krusei: epidemiology, clinical aspects, therapy. Clin Infect Dis 2002, 35:1066-1070.
85. Sobel JD, Zervos M, Reed BD, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003, 47:34-38.
86. MacNeill C, Weisz J, Carey JC Clinical resistance of recurrent Candida albicans vulvovaginitis to fluconazole in the presence and absence of in vitro resistance. J Reprod Med 2003, 48:63-68.
87. National Committee for Clinical Laboratory Standards Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Proposed Standard M27-T 1995, National Committee for Clinical Laboratory Standards, Wayne, PA.
88. Sobel JD, Chaim W Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997, 24:649-652.
89. Vazquez JA, Sobel JD, Demitriou R, et al. Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis 1994, 170:1566-1569.
90. Horowitz BJ, Edelstein SW, Lippman L Sexual transmission of Candida. Obstet Gynecol 1987, 69:883-886.
91. Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992, 116:353-357.
92. Gardner HL, Dukes CD Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified "nonspecific" vaginitis. Am J Obstet Gynecol 1955, 69:962-976.
93. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007, 34:864-869.
94. Speigel CA Bacterial vaginosis. Clin Microbiol Rev 1991, 4:485-502.
95. Brunham RC, Paavonen J, Stevens CE, et al. Mucopurulent cervicitis: the ignored counterpart in women of urethritis in men. N Engl J Med 1984, 311:1-6.
96. Eschenbach DA Bacterial vaginosis and anaerobes in obstetric-gynecologic infections. Clin Infect Dis 1993, 16(suppl 4):S282-S287.
97. Peipert JF, Mantagno AB, Cooper AS, et al. Bacterial vaginosis as a risk factor for upper genital tract infection. Am J Obstet Gynecol 1997, 177:1184-1187.
98. Sweet RL Role of bacterial vaginosis in pelvic inflammatory disease. Clin Infect Dis 1995, 20(suppl 2):S271-S275.
99. Pheifer TA, Forsyth PS, Durfee MA, et al. Nonspecific vaginitis: role of Haemophilus vaginalis and treatment with metronidazole. N Engl J Med 1978, 298:1429.
100. Chen KC, Forsyth PS, Buchanan TM, et al. Amine content of vaginal fluid from untreated and treated patients with nonspecific vaginitis. J Clin Invest 1979, 63:828-835.
101. Hanna NF, Taylor-Robinson D, Kalodiki-Karammonoki M, et al. The relation between vaginal pH and the microbiological status in vaginitis. Br J Obstet Gynaecol 1985, 92:1267-1271.
102. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983, 74:14-22.
103. Bhattacharyya MN, Jones BM Haemophilus vaginalis infection: diagnosis and treatment. J Reprod Med 1980, 24:71-75.
104. Spiegel CA, Amsel R, Holmes KK Diagnosis of bacterial vaginosis by direct Gram stain of vaginal fluid. J Clin Microbiol 1983, 18:170-177.
105. Fethers KA, Fairley CK, Hocking JS, et al. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis 2008, 47:1426-1435.
106. Berger BJ, Kolton S, Zenilman JM, et al. Bacterial vaginosis in lesbians: a sexually transmitted disease. Clin Infect Dis 1995, 21:1402-1405.
107. Evans AL, Scally AJ, Wellard SJ, et al. Prevalence of bacterial vaginosis in lesbians and heterosexual women in a community setting. Sex Transm Infect 2007, 83:470-475.
108. Ratnam S, Fitzgerald BL Semiquantitative culture of Gardnerella vaginalis in laboratory determination of nonspecific vaginitis. J Clin Microbiol 1983, 18:344-347.
109. Spear GT, Sikaroodi M, Zariffard MR, et al. Comparison of the diversity of the vaginal microbiota in HIV-infected and HIV-uninfected women with or without bacterial vaginosis. J Infect Dis 2008, 198:1131-1140.
110. Speigel CA, Roberts M Mobiluncus gen. nov., Mobiluncus curtisii subspecies curtisii sp. nov., Mobiluncus curtisii subspecies holmesii subsp. nov., and Mobiluncus mulieris sp. nov., curved rods from the human vagina. Int J Syst Bacteriol 1984, 34:177-184.
111. Menard J-P, Fenollar F, Henry M, et al. Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clin Infect Dis 2008, 47:33-43.
112. Brotman RM, Ghanem KG, Klebanoff MA, et al. The effect of vaginal douching cessation on bacterial vaginosis: a pilot study. Am J Obstet Gynecol 2008, 198:628.e7.
113. Brotman RM, Klebanoff MA, Nansel TR, et al. A longitudinal study of vaginal douching and bacterial vaginosis-a marginal structural modeling analysis. Am J Epidemiol 2008, 168:188-196.
114. Nagot N, Ouedraogo A, Defer MC, et al. Association between bacterial vaginosis and herpes simplex virus type-2 infection: implications for HIV acquisition studies. Sex Transm Infect 2007, 83:365-368.
115. Atashili J, Poole C, Ndumbe PM, et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008, 22:1493-1501.
116. Cu-Uvin S, Hogan JW, Caliendo AM, et al. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis 2001, 33:894-896.
117. Nugent RP, Krohn MA, Hillier SI Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991, 29:297-301.
118. McCormack WM, Covino JM, Thomason JL, et al. Comparison of clindamycin phosphate vaginal cream with triple sulfonamide vaginal cream in the treatment of bacterial vaginosis. Sex Transm Dis 2001, 28:569-575.
119. Schwebke JR, Hillier SL, Sobel JD, et al. Validity of the vaginal Gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol 1996, 88:573-576.
120. Fredricks DN, Fiedler TL, Thomas KK, et al. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 2007, 45:3270-3276.
121. Swedberg J, Steiner JF, Deiss F, et al. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. JAMA 1985, 254:1046-1049.
122. Hanson JM, McGregor JA, Hillier SL, et al. Metronidazole for bacterial vaginosis: a comparison of vaginal vs. oral therapy. J Reprod Med 2000, 45:889-896.
123. Schmitt C, Sobel JD, Meriwether C Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol 1992, 79:1020-1023.
124. Sobel J, Peipert JF, McGregor JA, et al. Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis. Infect Dis Obstet Gynecol 2001, 9:9-15.
125. Livengood CH, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 2007, 110:302-309.
126. Schwebke JR, Desmond RA A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 2007, 44:213-219.
127. Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 2008, 198:97.e6.
128. Verstraelen H, Swidsinski A The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment. Curr Opin Infect Dis 2013, 26:86-89.
129. Larsson PG, Carlsson B Does pre- and postoperative metronidazole treatment lower vaginal cuff infection rate after abdominal hysterectomy among women with bacterial vaginosis?. Infect Dis Obstet Gynecol 2002, 10:133-140.
130. Crowley T, Low N, Turner A, et al. Antibiotic prophylaxis to prevent post-abortal upper genital tract infection in women with bacterial vaginosis: randomized controlled trial. Br J Obstet Gynaecol 2001, 108:396-402.
131. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med 1995, 333:1737-1742.
132. Jacobsson B, Pernevi P, Chidekel L, et al. Bacterial vaginosis in early pregnancy may predispose for preterm birth and postpartum endometritis. Acta Obstet Gynecol Scand 2002, 81:1006-1010.
133. Leitich H, Bodner-Adler B, Brunbauer M, et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003, 189:139-147.
134. Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995, 333:1732-1736.
135. Morales WJ, Schorr S, Albritton J Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994, 171:345-349.
136. Leitcich H, Brunbauer M, Bodner-Adler B, et al. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am J Obstet Gynecol 2003, 188:752-758.
137. Ugwumadu A, Manyonda I, Reid F, et al. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003, 361:983-988.
138. Kekki M, Kurki T, Pelkonen J, et al. Vaginal clindamycin in preventing preterm birth and peripartum infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet Gynecol 2001, 97:643-648.
139. Koumans EH, Markowitz LE, Hogan V Indications for therapy and treatment recommendations for bacterial vaginosis in non-pregnant women: a synthesis of data. Clin Infect Dis 2002, 35(suppl 2):S152-S172.
140. McDonald HM, Brocklehurst P, Gordon A Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2007, (1).
141. Nygren P, Fu R, Freeman M, et al. Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. Preventive Services Task Force. Ann Intern Med 2008, 148:220-223.
142. U.S.Preventive Services Task Force Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 148:214-219.
143. Brocklehurst P, Gordon A, Heatley E, Milan SJ Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2013, (1).
144. Mehta SD Systematic review of randomized trials of treatment of male sexual partners for improved bacterial vaginosis outcomes in women. Sex Transm Dis 2012, 39:822-830.
145. Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 2013, 56:777-786.
146. Marrazzo JM Sexual networks, sex hormones, and recurrent bacterial vaginosis: not such strange bedfellows. Clin Infect Dis 2013, 56:787-789.
147. Sobel JD Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol 1994, 171:1215-1220.
148. Edwards L, Friedrich EG Desquamative vaginitis: lichen planus in disguise. Obstet Gynecol 1988, 71:832-836.
149. Bradford J, Fisher G Desquamative inflammatory vaginitis: differential diagnosis and alternate diagnostic criteria. J Low Genit Tract Dis 2010, 14:306-310.
150. Marrazzo JM, Martin DH Management of women with cervicitis. Clin Infect Dis 2007, 44(suppl 3):S102-S110.
151. Nyirjesy P Postmenopausal vaginitis. Curr Infect Dis Rep 2007, 9:480-484.
152. Palmer AR, Likis FE Lactational atrophic vaginitis. J Midwifery Womens Health 2003, 48:282-284.
153. Nyirjesy P Lichen sclerosus and other conditions mimicking vulvovaginal candidiasis. Curr Infect Dis Rep 2002, 4:520-524.
154. Friedrich EG Vulvar vestibulitis syndrome. J Reprod Med 1987, 32:110-114.
155. Peckham BM, Maki DG, Patterson JJ, et al. Focal vulvitis: a characteristic syndrome and cause of dyspareunia. Am J Obstet Gynecol 1986, 154:855-864.
156. Haefner HK, Collins ME, Davis GD, et al. The vulvodynia guideline. J Low Genit Tract Dis 2005, 9:40-51.
157. Goetsch MF Vulvar vestibulitis: prevalence and historic features in a general gynecologic practice population. Am J Obstet Gynecol 1991, 164:1609-1616.
158. McCormack WM, Spence MR Evaluation of the surgical treatment of vulvar vestibulitis. Eur J Obstet Gynecol Reprod Biol 1999, 86:135-138.
159. Tommola P, Unkila-Kallio L, Paavonen J Long-term well-being after surgical or conservative treatment of severe vulvar vestibulitis. Acta Obstet Gynecol Scand 2012, 91:1086-1093.
160. McCormack WM, Zinner SH, McCormack WM The incidence of genitourinary infections in a cohort of healthy women. Sex Transm Dis 1994, 21:63-64.
161. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 2011, 108(suppl 1):4680-4687.
162. 2-generating lactobacilli. J Infect Dis 1991, 164:94-100.
163. Soper DE, Bump RC, Hurt WG Bacterial vaginosis and trichomoniasis are risk factors for cuff cellulitis after abdominal hysterectomy. Am J Obstet Gynecol 1990, 163:1016-1023.
164. Singh RH, Zenilman JM, Brown KM, et al. The role of the physical examination in diagnosing common causes of vaginitis: a prospective study. Sex Transm Infect 2013, 89:185-190.
165. McCormack WM, Starko KM, Zinner SH Symptoms associated with vaginal colonization with yeast. Am J Obstet Gynecol 1988, 158:31-33.
166. Lossick JG, Kent HL Trichomoniasis: trends in diagnosis and management. Am J Obstet Gynecol 1991, 165:1217-1222.
167. DeMeo LR, Draper DL, McGregor JA, et al. Evaluation of a deoxyribonucleic acid probe for the detection of Trichomonas vaginalis in vaginal secretions. Am J Obstet Gynecol 1996, 174:1339-1342.
168. Workowski KA, Berman SM Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006, 55(RR-11):1-94. Centers for Disease Control and Prevention.
169. Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD surveillance network, 2009-2010. Emerg Infect Dis 2012, 18:939-943.
170. Lossick JG, Muller M, Gorrell TE In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis 1986, 153:948-955.
171. Nailor MD, Sobel JD Tinidazole for the treatment of vaginal infections. Expert Opin Investig Drugs 2007, 16:743-751.
172. duBouchet L, McGregor JA, Ismail M, et al. A pilot study of metronidazole vaginal gel versus oral metronidazole for the treatment of Trichomonas vaginalis vaginitis. Sex Transm Dis 1998, 24:176-179.
173. Sharma R, Pickering J, McCormack WM Trichomoniasis in a postmenopausal woman cured after discontinuation of estrogen replacement therapy. Sex Transm Dis 1997, 24:543-545.
174. Helms DJ, Mosure DJ, Secor WE, et al. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008, 198:370.e7.
175. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001, 345:487-493.
176. Caro-Paton T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997, 44:179-182.
177. Piper JM, Mitchel EF, Ray WA Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993, 82:348-352.
178. Horowitz BJ, Edelstein SW, Lippman L Candida tropicalis vulvovaginitis. Obstet Gynecol 1985, 66:229-232.
179. Ray D, Goswami R, Banerjee U, et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007, 30:312-317.
180. Sobel JD, Vazquez J, Lynch M, et al. Vaginitis due to Saccharomyces cerevisiae: epidemiology, chemical aspects, and therapy. Clin Infect Dis 1993, 16:93-99.
181. Sobel JD Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985, 1523:924-935.
182. Larsen B Vaginal flora in health and disease. Clin Obstet Gynecol 1993, 36:107-121.
183. Sobel JD Vaginitis. N Engl J Med 1997, 337:1896-1903.
184. Ferris DG, Nyirjesy P, Sobel JD, et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 2002, 99:419-425.
185. Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Am J Obstet Gynecol 1995, 172:1263-1268.
186. Nyirjesy P, Seeney SM, Terry Grody MH, et al. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol 1995, 173:820-823.
187. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004, 351:876-883.
188. Sobel JD, Chaim W Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997, 24:649-652.
189. Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992, 116:353-357.
190. Gardner HL, Dukes CD Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified "nonspecific" vaginitis. Am J Obstet Gynecol 1955, 69:962-976.
191. Brunham RC, Paavonen J, Stevens CE, et al. Mucopurulent cervicitis: the ignored counterpart in women of urethritis in men. N Engl J Med 1984, 311:1-6.
192. Eschenbach DA Bacterial vaginosis and anaerobes in obstetric-gynecologic infections. Clin Infect Dis 1993, 16(suppl 4):S282-S287.
193. Pheifer TA, Forsyth PS, Durfee MA, et al. Nonspecific vaginitis: role of Haemophilus vaginalis and treatment with metronidazole. N Engl J Med 1978, 298:1429.
194. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983, 74:14-22.
195. Berger BJ, Kolton S, Zenilman JM, et al. Bacterial vaginosis in lesbians: a sexually transmitted disease. Clin Infect Dis 1995, 21:1402-1405.
196. Speigel CA, Roberts M Mobiluncus gen. nov., Mobiluncus curtisii subspecies curtisii sp. nov., Mobiluncus curtisii subspecies holmesii subsp. nov., and Mobiluncus mulieris sp. nov., curved rods from the human vagina. Int J Syst Bacteriol 1984, 34:177-184.
197. Nugent RP, Krohn MA, Hillier SI Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991, 29:297-301.
198. McCormack WM, Covino JM, Thomason JL, et al. Comparison of clindamycin phosphate vaginal cream with triple sulfonamide vaginal cream in the treatment of bacterial vaginosis. Sex Transm Dis 2001, 28:569-575.
199. Schwebke JR, Hillier SL, Sobel JD, et al. Validity of the vaginal Gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol 1996, 88:573-576.
200. Larsson PG, Carlsson B Does pre- and postoperative metronidazole treatment lower vaginal cuff infection rate after abdominal hysterectomy among women with bacterial vaginosis?. Infect Dis Obstet Gynecol 2002, 10:133-140.
201. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med 1995, 333:1737-1742.
202. Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995, 333:1732-1736.
203. Koumans EH, Markowitz LE, Hogan V Indications for therapy and treatment recommendations for bacterial vaginosis in non-pregnant women: a synthesis of data. Clin Infect Dis 2002, 35(suppl 2):S152-S172.
204. U.S.Preventive Services Task Force Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 148:214-219.
205. Sobel JD Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol 1994, 171:1215-1220.
206. Marrazzo JM, Martin DH Management of women with cervicitis. Clin Infect Dis 2007, 44(suppl 3):S102-S110.
207. Nyirjesy P Lichen sclerosus and other conditions mimicking vulvovaginal candidiasis. Curr Infect Dis Rep 2002, 4:520-524.
208. Peckham BM, Maki DG, Patterson JJ, et al. Focal vulvitis: a characteristic syndrome and cause of dyspareunia. Am J Obstet Gynecol 1986, 154:855-864.
209. Goetsch MF Vulvar vestibulitis: prevalence and historic features in a general gynecologic practice population. Am J Obstet Gynecol 1991, 164:1609-1616.
210. McCormack WM, Spence MR Evaluation of the surgical treatment of vulvar vestibulitis. Eur J Obstet Gynecol Reprod Biol 1999, 86:135-138.